• DOI:10.1007/BF03401287
Corpus ID: 4716903

The evolution in the use of MIBG scintigraphy in pheochromocytomas and paragangliomas

@article{Rufini2013TheEI,
  title={The evolution in the use of MIBG scintigraphy in pheochromocytomas and paragangliomas},
  author={V. Rufini and G. Treglia and G. Perotti and A. Giordano},
  journal={Hormones},
  year={2013},
  volume={12},
  pages={58-68}
}

V. Rufini, G. Treglia, +1 author A. Giordano

Published 2013

Medicine

Hormones

Radioiodinated metaiodobenzylguanidine (MIBG) was developed in the late 1970’s, at the Michigan University Medical center, for imaging of the adrenal medulla and its diseases. Soon after, MIBG was shown to depict a wide range of tumors of neural crest origin other than pheochromocytomas/paragangliomas (Pheo/PGL) with the result that its use rapidly spread to many countries. After more than 30 years of clinical application, MIBG continues to be the most widespread radiopharmaceutical for the… CONTINUE READING

View on Springer

hormones.gr

Save to Library

Create Alert

Cite

Launch Research Feed